Riskpilot← Back to searchSign inGet full accessHOLMLIA APOTEK AS
ASActiveOrg 816121612Asperudveien 67, 1255 OsloRetail sale of pharmaceutical products · NACE 4773Est. 201519 employees
Revenue 2025
NOK 22,8M
+5% vs 2024
EBITDA margin
1.8%
+100% vs 2024
Equity ratio
7.7%
Financial strength
Net profit 2025
NOK 292K
+137% vs 2024
| Revenue | NOK 22,8M | +5% |
| EBITDA | NOK 399K | +100% |
| Net profit | NOK 292K | +137% |
| Total assets | NOK 3,6M | +25% |
| Equity | NOK 275K | -43% |
| Employees | 19 | — |
Legal name
HOLMLIA APOTEK AS
Org number
816121612
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
23. oktober 2015
Share capital
NOK 30 000
Employees
19 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder alene. Styrets leder alene.
Company purpose
Eie og drive apotek, herunder konsulenttjenester innenfor apotekerbransjen og lege- og helserelaterte produkter, samt øvrig virksomhet i tilknytning til dette.
Address
Asperudveien 67, 1255 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 28 026 | 22 223 | 21 626 | 21 732 | 22 755 |
| Staff expenses | −5 360 | −4 047 | −4 069 | −3 994 | −3 743 |
| EBITDA | 1 370 | 655 | 539 | 200 | 399 |
| Depreciation & amort. | −40 | −32 | −26 | −37 | −13 |
| EBIT | 1 330 | 623 | 514 | 163 | 386 |
| Net financials | −6 | 1 | 12 | −3 | 1 |
| Profit before tax | 1 324 | 623 | 526 | 160 | 387 |
| Tax | 292 | 139 | 116 | 37 | 95 |
| Net profit | 1 032 | 484 | 410 | 123 | 292 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 5 508 | 3 771 | 4 142 | 2 850 | 3 574 |
| Equity | 1 466 | 951 | 360 | 484 | 275 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 041 | 2 821 | 3 781 | 2 367 | 3 299 |
| Total debt | 4 041 | 2 821 | 3 781 | 2 367 | 3 299 |
EBITDA margin
1.8%
This company
15.8%
Market median
-89% vs market
20212025
Equity ratio
7.7%
This company
38.2%
Market median
-80% vs market
20212025
Return on equity
106.0%
This company
18.4%
Market median
+476% vs market
20212025
Net profit margin
1.3%
This company
8.1%
Market median
-84% vs market
20212025
Asset turnover
6.37×
This company
1.12×
Market median
+469% vs market
20212025
Debt / equity
11.97×
This company
0.62×
Market median
-1831% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HA Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 49% | 49% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Mckesson Norway Holding As
HOLMLIA APOTEK AS Board members of HOLMLIA APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hafsa Ali | Chief Executive Officer | 0 companies |
| Bård Andersen | Chairman | 0 companies |
| Johan Fredrik Balstad | Board of Directors | 0 companies |